<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04786886</url>
  </required_header>
  <id_info>
    <org_study_id>20190679</org_study_id>
    <nct_id>NCT04786886</nct_id>
  </id_info>
  <brief_title>Patient Performance and Acceptance of Virtual Reality Visual Field Devices</brief_title>
  <official_title>Patient Performance and Acceptance of Virtual Reality Visual Field Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the effectiveness and patient experience when&#xD;
      measuring visual fields using virtual reality goggles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Actual">February 2, 2021</completion_date>
  <primary_completion_date type="Actual">February 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operational Effectiveness</measure>
    <time_frame>Day 1</time_frame>
    <description>Operational effectiveness will be reported as the length of the visit and virtual reality visual field exam testing times. Both will be measured in minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical Effectiveness as Measured by Visual Field Indexes</measure>
    <time_frame>Day 1</time_frame>
    <description>Medical effectiveness will be evaluated by visual field indexes, such as mean deviation, pattern standard deviation, and foveal threshold, which are all measured in decibels. These values are generated based on the participants' performance in the visual field exam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical Effectiveness as Measured by Glaucoma Hemifield Test</measure>
    <time_frame>Day 1</time_frame>
    <description>Medical effectiveness will be evaluated by the glaucoma hemifield test. This value is generated based on the participants' performance in the visual field exam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reliability Indices</measure>
    <time_frame>Day 1</time_frame>
    <description>Reliability index is generated based on the participants' performance in the visual field exam.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Visual Field Defect, Peripheral</condition>
  <condition>Visual Field Defect, Nasal Step</condition>
  <condition>Visual Field Defect, Paracentral Scotoma of Both Eyes</condition>
  <arm_group>
    <arm_group_label>Virtual Reality Visual Field Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will have virtual reality visual field testing during standard of care follow-up visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VIrtual Reality Visual Field Exam</intervention_name>
    <description>Virtual reality visual field exam will be administered using the virtual reality headset. Exams can take up to 20 minutes.</description>
    <arm_group_label>Virtual Reality Visual Field Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient &gt;13 years old at Bascom Palmer Eye Institute&#xD;
&#xD;
          -  Patients who either have glaucoma, are glaucoma suspects, or have a strong family&#xD;
             history of glaucoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent, pregnant women, prisoners&#xD;
&#xD;
          -  Patients under the age of 13&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alana Grajewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Alana L Grajewski</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Retinal Sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scotoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

